Robert Marcus, MA, FRCP, FRCPath from King’s College Hospital, London, UK discusses the GALLIUM study at the 2017 British Society for Haematology (BSH) Annual Scientific Meeting in Brighton, UK. The GALLIUM study (NCT01332968) was a randomised trial comparing obinutuzumab plus chemotherapy and rituximab plus chemotherapy with rituximab and obinutuzimab maintenance. When the trial was designed, the aim was to demonstrate a 2 year improvement in progression free survival. This result was exceeded in all treatment regimens; CVP, CHOP, and bendamustine. There were some unexpected toxicities and deaths in the bendamustine arm, which may lead to bendamustine being prescribed with caution. This video has been supported by Napp Pharmaceuticals Ltd through an unrestricted educational grant to Magdalen Medical Publishing.